

Cite this: *Chem. Sci.*, 2016, 7, 6251

# The rational design of specific SOD1 inhibitors *via* copper coordination and their application in ROS signaling research†

Xiongwei Dong,‡ Zhe Zhang,‡ Jidong Zhao, Juan Lei, Yuanyuan Chen, Xiang Li, Huanhuan Chen, Junli Tian, Dan Zhang, Chunrong Liu\* and Changlin Liu\*

Efficient methods for the regulation of intracellular  $O_2^{\cdot-}$  and  $H_2O_2$  levels, without altering intracellular processes, are urgently required for the rapidly growing interest in ROS signaling, as ROS signaling has been confirmed to be involved in a series of basic cellular processes including proliferation, differentiation, growth and migration. Intracellular  $H_2O_2$  is formed mainly *via* the catalytic dismutation of  $O_2^{\cdot-}$  by SODs including SOD1, SOD2 and SOD3. Thus, the intracellular levels of  $O_2^{\cdot-}$  and  $H_2O_2$  can directly be controlled through regulating SOD1 activity. Here, based on the active site structure and catalytic mechanism of SOD1, we developed a new type of efficient and specific SOD1 inhibitors which can directly change the intracellular levels of  $H_2O_2$  and  $O_2^{\cdot-}$ . These inhibitors inactivate intracellular SOD1 *via* localization into the SOD1 active site, thereby coordinating to the  $Cu^{2+}$  in the active site of SOD1, blocking the access of  $O_2^{\cdot-}$  to  $Cu^{2+}$ , and breaking the  $Cu^{2+}/Cu^+$  catalytic cycle essential for  $O_2^{\cdot-}$  dismutation. The reduced ERK1/2 phosphorylation induced by the specific SOD1 inactivation-mediated decrease of intracellular  $H_2O_2$  levels reveals the potential of these specific SOD1 inhibitors in understanding and regulating ROS signaling. Furthermore, these specific SOD1 inhibitors also lead to selectively elevated cancer cell apoptosis, indicating that these kinds of SOD1 inhibitors might be candidates for lead compounds for cancer treatment.

Received 21st March 2016

Accepted 15th June 2016

DOI: 10.1039/c6sc01272h

www.rsc.org/chemicalscience

## Introduction

Reactive oxygen species (ROS) are formed upon incomplete reduction of dioxygen and include the superoxide anion ( $O_2^{\cdot-}$ ), hydrogen peroxide ( $H_2O_2$ ) and the hydroxyl radical ( $HO^{\cdot}$ ). Over the past two decades, physiological roles of  $H_2O_2$  and perhaps  $O_2^{\cdot-}$  have been established in cell signaling and transcription regulation. Diverse signaling pathways regulated by ROS include extracellular signal-regulated kinase1/2 (ERK1/2), nuclear factor  $\kappa$ B (NF- $\kappa$ B), c-Jun N-terminal kinase (JNK), focal adhesion kinase (FAK), hypoxia-inducible factor (HIF), AP-1, Nrf2, PI3K/Akt, Ras, Rac, HIP, and JAK-STAT.<sup>1–5</sup> A current concept is that ROS regulate the signaling pathways triggered by both cytokines and transcription factors that ultimately control cell proliferation and differentiation, all of which are important hallmarks of tumorigenesis and angiogenesis.<sup>6–9</sup> Furthermore, ROS act as a mediator of inflammation in neurodegeneration *via* regulation of the signaling pathways including NF- $\kappa$ B and

AP-1.<sup>10</sup> Thus, ROS regulation of signaling pathways has attracted much interests and research.<sup>1–12</sup> Although the research on ROS signaling in the past two decades has rapidly shaped our understanding of a range of topics, including metabolic regulation, innate immunity, stem cell biology, pathogenesis of related diseases such as cancer, and aging, questions still remain: *e.g.*, the question of how and at which level the intracellular ROS can function within various signaling pathways, and whether controlling intracellular ROS levels could be used in the treatment of related diseases. To provide answers to these questions, an efficient method for controlling intracellular ROS levels (especially  $H_2O_2$ ) without altering cellular processes is required. Furthermore, there are also several drawbacks to be overcome in current ROS signaling research. First, because the signaling regulation is dependent on the concentration of  $H_2O_2$ , the research is always carried out *via* direct exposure of cells to external  $H_2O_2$  at concentrations much higher than the intracellular basal levels of  $H_2O_2$ .<sup>13–24</sup> Evidently, the external  $H_2O_2$  of high concentrations can notably interfere with many normal cellular processes. Then, growth factors are used to stimulate cells to produce high levels of ROS, but they can also alter the expression of many genes in the cells.<sup>20,25–27</sup> It is possible that the stimulation with either external  $H_2O_2$  or growth factors leads the treated cells to produce artificial phenomena. Therefore, if the intracellular ROS level can directly be altered without

Key Laboratory of Pesticide & Chemical Biology, Ministry of Education, School of Chemistry, Central China Normal University, Wuhan 430079, Hubei, China. E-mail: liuchl@mail.ccnu.edu.cn; liucr@mail.ccnu.edu.cn

† Electronic supplementary information (ESI) available: Experimental methods and any associated references. Table S1, Fig. S1–S10. See DOI: 10.1039/c6sc01272h

‡ These authors contributed equally.



these two kinds of external stimulations, it is possible to avoid certain artificial phenomena in both the understanding and regulation of ROS signaling.

The signaling species  $\text{H}_2\text{O}_2$  is formed *via* the catalytic dismutation of  $\text{O}_2^{\cdot-}$  (with a rate constant up to  $10^9 \text{ M}^{-1} \text{ s}^{-1}$ ) mainly by copper/zinc superoxide dismutase (SOD1), a key antioxidant enzyme that is widely distributed in a cell.<sup>28,29</sup> This indicates that the intracellular ROS levels can be controlled by regulating SOD1 activity, *i.e.*, ROS signaling can be regulated by inhibiting or elevating SOD1 activity because of the dependence of the signaling regulation on intracellular ROS levels.<sup>14–27</sup> Indeed, SOD1 is essential for  $\text{H}_2\text{O}_2$ -mediated oxidation and inactivation of protein tyrosine phosphatases (PTPs) in growth factor signaling,<sup>30</sup> and can integrate signals from oxygen and glucose to repress respiration with its normal enzymatic activity.<sup>31</sup> Both too high and too low SOD1 activities can lead to aberrant cellular ROS signaling that is linked to inflammation, amyotrophic lateral sclerosis (ALS), malignant cell proliferation, tumorigenesis and angiogenesis,<sup>32–35</sup> which makes the enzyme a key target for drug design for cancer and ALS therapy.<sup>36,37</sup> Moreover, controlling the intracellular SOD1 activity is essential to address the long-standing problem that intracellular ROS levels can't be directly regulated without external stimulation in the research and regulation of ROS signaling.

SOD1 activity can be inhibited by either SOD1 siRNAs or small molecular inhibitors. Although the siRNAs can specifically reduce the expression of the SOD1 protein *via* targeting SOD1 mRNA, their inhibition efficacy is limited.<sup>30</sup> Several small molecular inhibitors of SOD1 have been developed and can be divided into two classes: the chelators that target the copper ion in the active site of SOD1, because each subunit in the homodimeric enzyme hosts a copper ion responsible for its function; and the organic molecules that bind to other sites in SOD1, *e.g.*, 4,5-dichloro-2-*m*-tolyl pyridazin-3(2*H*)-one (LCS-1).<sup>37</sup> Among these inhibitors, diethyldithiocarbamate (DDC) and tetrathiomolybdate (TM) are two of the most studied kinds of copper-chelating inhibitors of SOD1. On the one hand, *in vitro* tests showed that DDC and its derivatives can efficiently inhibit SOD1 at more than millimolar concentrations, but whether they can specifically inactivate SOD1 activity or not remains to be explored.<sup>38–42</sup> On the other hand, TM was found to efficiently inhibit SOD1 *via* partially removing copper from the enzyme.<sup>43,44</sup> The TM inhibition of SOD1 leads to the down-regulation of growth factor-mediated phosphorylation of ERK1/2 (ref. 30), and the expression of both cytokines and transcription factors such as NF- $\kappa$ B.<sup>45,46</sup> A derivative of TM (ATN-224) was reported to efficiently suppress angiogenesis and tumor growth through targeting SOD1,<sup>47–49</sup> and is being tested in phase I and II clinical studies as an anticancer drug.<sup>45–50</sup> However, in addition to inhibition of SOD1, TM can also inactivate a series of copper enzymes including cytochrome c oxidase (CcO), ascorbate oxidase, ceruloplasmin, tyrosinase, and the *Enterococcus hirae* adenosine triphosphatase, and binds to copper ions in metallothioneins.<sup>51–53</sup> Moreover, the copper trafficking essential for normal cellular functions is blocked by the formation of a TM–Cu cluster in the copper chaperone Atox1, rather than by the removal of copper from Atox1.<sup>54</sup> In addition, the antibiotic

clioquinol was also reported to be capable of inhibiting SOD1 in solutions, but without evidence to exclude other intracellular targets.<sup>55</sup> Thus, the development of specific and effective inhibitors of SOD1 is urgently required not only for the research into and regulation of ROS signaling, but also for the design of drugs targeting SOD1.


Here, based on the copper coordination chemistry and catalytic cycle in the active site of SOD1, for the first time to our knowledge, a series of specific copper-coordinating inhibitors of SOD1 were designed by combining phenol, thiosemicarbazone, pyridine derivatives, and chromone. The  $\text{IC}_{50}$  values for the inhibition of intracellular SOD1 activity approach nano-molar levels, and the SOD1 activity within the treated cells can be reduced to  $\leq 20\%$  of that within the untreated cells. Furthermore, the activity of not only the copper enzymes including CcO and tyrosinase, but also the copper trafficking proteins including Atox1 is completely unaffected by these inhibitors. The inhibition of SOD1 leads to reduced intracellular  $\text{H}_2\text{O}_2$  and increased intracellular  $\text{O}_2^{\cdot-}$  levels. These alterations in the intracellular ROS levels are correlated well with the reduction of ERK1/2 phosphorylation, a key step in the mitogen-activated protein kinase (MAPK) pathway. Thus, this study established the power of this kind of specific SOD1 inhibitor in the understanding and regulation of ROS signaling. Moreover, these inhibitors also promote apoptosis of cancer cells, revealing their potential to be harnessed as anti-cancer leading structures.

## Results and discussion

### Design of the copper-coordinating inhibitors of SOD1

When copper-coordinating inhibitors of SOD1 are designed based on both the copper coordination chemistry and the catalytic cycle in the active site of the enzyme (Fig. 1a),<sup>56</sup> the pivotal factors to be considered include: (1) the stability constants of their copper complexes, which should be much higher than the affinity constant of SOD1 proteins for copper ( $K_d \sim 10^{-16} \text{ M}$  for  $\text{Cu}^+$ ,<sup>57</sup> and  $\sim 10^{-14} \text{ M}$  for  $\text{Cu}^{2+}$  (ref. 43)); (2) their coordination to copper, which could block the cyclic redox reactions of copper with  $\text{O}_2^{\cdot-}$  in SOD1, and (3) their appropriate localization, which can not only prevent the access of  $\text{O}_2^{\cdot-}$  to the copper ion in SOD1 through the electrostatic channel with positive potential, but can also disrupt the noncovalent interactions between the  $\text{Cu}^{2+}$ -bound  $\text{O}_2^{\cdot-}$  and the residue Arg141 in the catalytic cycle of SOD1.<sup>56</sup> Based on these considerations, a series of  $\text{Cu}^{2+}$ -chelating agents were designed *via* a combination of thiosemicarbazone and phenol or pyridine derivatives (Fig. 1b). The thiosemicarbazone contains a strongly copper-chelating and a H-bonding moiety  $-\text{C}(\text{SH})-\text{NH}-$ . The thiosemicarbazone complexes formed with  $\text{Cu}^{2+}$  (*e.g.*,  $\text{CuATSM}$ ,  $\text{ATSM} = \text{diacetyl}(\text{bis-}N(4)\text{-methylthiosemicarbazone})$ ) have potential uses in chemotherapeutics, and diagnostic and therapeutic radiopharmaceuticals,<sup>58</sup> whereas the phenolic hydroxyl or pyridine nitrogen in these chelators further facilitates the coordination of copper. To directly observe the entrance of the chelators into a cell, a fluorescent group chromone was covalently linked to the chelators (Fig. 1b, **LD93**, **94**, **100**).





**Fig. 1** The design of SOD1 inhibitors. (a) The proposed inhibitor-targeted sites (blue) in the active site and catalytic cycle of SOD1 are indicated by the red circles. (b) The design strategy and representatives of the  $\text{Cu}^{2+}$ -coordinating inhibitors of SOD1. (c) The proposed interactions between a SOD1 molecule and the inhibitor LD34 (left) or LD100 (right) based on molecular docking simulations.

In order to obtain data to support this design, based on the SOD1 structural data (PDB SOD1, 1CBJ), molecular docking simulations were carried out using the AutoDock program (version 4.2.0). The well-docked clusters (RMSD, Root-Mean-Square Deviation < 2.0 Å) in the top-ranked poses were enumerated. The results indicate that the flexible chelator molecules can be localized into the active site in SOD1 because of their perfect match with both the active site and the substrate channel of SOD1 in both size and hydrophobicity, and this localization can be stabilized mainly *via* both the coordination of the sulfur atom in the chelators to  $\text{Cu}^{2+}$  in the SOD1 active site ( $\text{Cu}^{2+}$ -S distances = 3.46–4.27 Å) and the H-bonds between the chelators and the SOD1 residues, in particular, the unexpected H-bonds between the LD100 chromone group and the

SOD1 residues Thr135 and Gly139 (Fig. 1c). Obviously, this localization of the chelators can not only hinder the access of  $\text{O}_2^{\cdot-}$  to the active site  $\text{Cu}^{2+}$  ion, but can also disrupt the non-covalent interactions between the  $\text{Cu}^{2+}$ -bound  $\text{O}_2^{\cdot-}$  and Arg141 because of the H-bonds between the chelator -NH- group and the residue Arg 141 (Fig. 1c).

Because the design strategy was supported by the molecular docking simulations, a series of copper chelators for the inhibition of SOD1 activity were synthesized and characterized (see ESI† for synthesis programs). The fluorescence properties and metal ion selectivity of the chelators modified with chromone are displayed in ESI Fig. 1.†

### Characterization of coordination of the chelators to copper

The acidity constants of the chelators and the stability constants of their complexes formed respectively with  $\text{Cu}^{2+}$ ,  $\text{Zn}^{2+}$ ,  $\text{Mn}^{2+}$  and  $\text{Fe}^{2+}$  were determined *via* potentiometric titrations at 25 °C. The acidity constants ( $\text{pK}_{\text{a}1}$  to  $\text{pK}_{\text{a}4}$ ) of the chelators are listed in ESI Table 1.† The calculations performed using the titration data showed that (1) the  $\text{Cu}^{2+}$  complexes have large stability constants ( $K_{\text{Cu}^{2+}} \geq 10^{18} \text{ M}^{-1}$ , *i.e.*,  $K_{\text{d,Cu}^{2+}} \leq 10^{-18} \text{ M}$ , Table 1) when the chelators contain a sulfur atom as a coordination atom to  $\text{Cu}^{2+}$ , and (2) covalent linking of the chromone can significantly elevate the coordination ability of the chelators (LD93, 94, 100). Evidently, these results demonstrated that the  $\text{Cu}^{2+}$  affinity of all of the designed chelators is much greater than the  $\text{Cu}^{2+}$  affinity of SOD1 proteins.<sup>43</sup> In addition, the stability constants of the  $\text{Cu}^{2+}$  complexes are 1–3 orders of magnitude higher than those of the complexes with the other divalent metal ions tested (Table 1), indicating that the chelators have notable selectivity for  $\text{Cu}^{2+}$  over the other divalent metal ions tested.

Solution speciation diagrams were calculated for the coordination of the chelators to  $\text{Cu}^{2+}$  (ESI Fig. 2†) using the stability constants (Table 1). These diagrams suggested that the 1 : 1 and 2 : 2  $\text{Cu}^{2+}$ -chelator complexes are the predominant species formed in the range of pH 5–8 (Table 1). This pH range requisite for the formation of stable complexes completely covers the pH range of the optimal SOD1 activity. The 1 : 1 and 2 : 2 complexes were confirmed by the X-ray crystal structures of the  $\text{Cu}^{2+}$  complexes formed with some of the chelators (ESI Fig. 3†).

In order to examine whether the coordination of the chelators can make the  $\text{Cu}^{2+}$  ion become redox-inactive, we observed the redox behavior of the  $\text{Cu}^{2+}$  complexes with cyclic voltammograms. The cyclic voltammograms of all of the complexes showed only a distinct cathode peak at  $\sim -0.3 \text{ V}$  in anhydrous DMF at a glassy carbon working electrode (ESI Fig. 4,† see Table 1 for the separation data between the anode and cathode peak potentials), indicating that the  $\text{Cu}^{2+}$  ion in the complexes does not undergo a reversible redox process.<sup>59</sup> Therefore, the binding of the chelators may partly disrupt the reversible redox cycle between  $\text{Cu}^{2+}$  and  $\text{Cu}^+$  of the chelated copper.

### Inhibition of SOD1 activity

The above-described results indicated that the chelators could compete for the  $\text{Cu}^{2+}$  ion in the SOD1 active site *via*



Table 1 The data for coordination with different divalent metal ions and IC<sub>50</sub> of the chelators

Chelators	LD18	LD25	LD27	LD29	LD34	LD93	LD94	LD100
log $K_{Cu^{2+}}$ , $n = 1$ , $M^{-1}$	19.90	18.43	16.74	17.97	19.12	19.46	20.01	20.06
log $K_{Zn^{2+}}$ , $n = 1$ , $M^{-1}$	17.82	17.37	16.65	17.64	15.93	18.40	17.07	17.34
log $K_{Mn^{2+}}$ , $n = 1$ , $M^{-1}$	17.62	15.89	16.11	15.20	16.62	16.66	16.20	16.30
log $K_{Fe^{2+}}$ , $n = 1$ , $M^{-1}$	17.09	17.08	16.13	17.24	17.02	17.94	17.42	18.24
$K_{Cu^{2+}}/K_{Zn^{2+}}$	$1.20 \times 10^2$	$1.15 \times 10^1$	1.23	2.14	$1.55 \times 10^3$	$1.15 \times 10^1$	$8.71 \times 10^2$	$5.25 \times 10^2$
$K_{Cu^{2+}}/K_{Mn^{2+}}$	$1.91 \times 10^2$	$3.47 \times 10^2$	4.27	$5.89 \times 10^2$	$3.16 \times 10^3$	$6.31 \times 10^2$	$6.46 \times 10^3$	$5.75 \times 10^3$
$K_{Cu^{2+}}/K_{Fe^{2+}}$	$6.46 \times 10^1$	$2.24 \times 10^1$	4.07	5.37	$1.26 \times 10^2$	$3.31 \times 10^1$	$3.89 \times 10^2$	$6.6 \times 10^1$
pH range for $Cu^{2+}$ complexes	4–8	7–10	5–8	5–8	4–8	4–8	5–10	4–9
$\Delta E_p$ , mV	0.137	0.130	0.135	0.132	0.159	0.123	0.172	0.155
$i_{pa}/i_{pc}$	0.21	0.18	—	0.19	0.15	—	—	0.071
IC <sub>50</sub> , $\mu M$	12.31	2.12	2.92	1.36	0.79	1.46	0.21	0.18

coordination. Thus, first, we determined the inhibition of bovine SOD1 activity caused by this competition for  $Cu^{2+}$  in pH 7.4 buffer. The results show that the treatment with 5  $\mu M$  chelators for 60 min causes the SOD1 (1  $\mu M$ ) activity to be reduced to 16–40% of the control, whereas the SOD1 treated with either 5  $\mu M$  ATSM or DDC, in comparison, maintains >60% activity under the conditions tested (Fig. 2a). Obviously, these data indicated that the chelators designed here are strong inhibitors of SOD1 under neutral conditions, and the inhibitory effect decreased in the order of **LD100** > **94** ~ **27** ~ **29** ~ **34** > **93** ~ **74** ~ **25** > **18** ~ **61** ~ **81** ~ **82** > **72** ~ **83** ~ **84**.

Then, we examined HeLa cell uptake of the chelators prior to the determination of the inhibition of intracellular SOD1 activity, because only the chelators taken up by the cell may approach the SOD1 active site in the cytoplasm. The chelators **LD94** and **100** were selected to perform this examination because they carry the covalently linked fluorescent group chromone and facilitate visualization of the intracellular chelators under a confocal microscope. The confocal imaging shows that (1) the fluorescent chelators distribute over all of the intracellular area besides the nucleus following incubation for 2–4 h, and the incubation for 2 h leads to the strongest green fluorescence, and (2) the cells exposed to **LD100** display much more brilliant green fluorescence than those exposed to **LD94** (Fig. 2b). These results indicated that (1) the chelators tested are not only easily taken up by the cell, but also maintain a long stay in the cytoplasm, and (2) the chlorine substituent in **LD100** can elevate the cell uptake of the chelator compared to **LD94**.

The easy entrance into cells and the intracellular long stay observed above could underlie the inhibition of intracellular SOD1 activity by the chelators. Thus, the chelators **LD18**, **25**, **27**, **29**, **34**, **93**, **94**, and **100** were selected for tests of the intracellular SOD1 inhibition. The SOD1 activity within the HeLa cells after being treated, respectively, with the chelators, ATSM and TM, was assayed under the conditions tested. Following treatment for 24 h, the examination of the dependence of the intracellular SOD1 inhibition on chelator concentrations showed that (1) the SOD1 activity is reduced to ~20% of and even less than 20% of the initial activity as concentrations of the chelators are increased from 0.1  $\mu M$  to 50  $\mu M$ , and (2) the different inhibitors do not display significantly different inhibition when their concentrations are  $\geq 10$   $\mu M$  (Fig. 2c). The 50% inhibitory


concentrations (IC<sub>50</sub>,  $\mu M$ ) of the SOD1 activity were obtained using these concentration dependences of the SOD1 inhibition (Table 1 and ESI Fig. 5†), indicating that half of the chelators tested have IC<sub>50</sub> values that approach nM scales (e.g., **LD94**, **100**) and are much less than those of TM (one of the strongest inhibitors of SOD1 activity tested so far<sup>30</sup>) and ATSM. In addition, the SOD1 activity within the cells incubated for varied periods with **LD100** was observed to be reduced with prolonging incubation time, indicating the time dependence of the SOD1 inhibition (Fig. 2c). These results proved that incubation with the chelators can efficiently inactivate the intracellular SOD1.

In order to understand the strong inhibition of SOD1 activity, the possible interactions between the chelators and SOD1 were examined using molecular docking simulations using an AutoDock program. The simulation suggested that the chelators approach the metal active site in SOD1 likely *via* the hydrophobic and H-bonding interactions with some interior groups of the enzyme. The chelator molecules must alter their conformation to adapt to the shape of the active site and to form H-bonds between their certain groups and the SOD1 residues Arg141, His61, Thr135, and Gly139 (see the H-bonds indicated in Fig. 1c). The H-bond between the chromone C=O group and Arg141 not only disrupts the noncovalent interactions between Arg141 and the  $Cu^{2+}$ -bound  $O_2^{\cdot-}$  that are essential for the catalytic dismutation of  $O_2^{\cdot-}$ , but also fills the substrate channel in SOD1. Both the conformational alteration and the formation of these H-bonds could facilitate the coordination of the chelator sulfur atom to the active site  $Cu^{2+}$  ion ( $Cu^{2+}$ -S distances = 3.46–4.27 Å, Fig. 2d). This  $Cu^{2+}$ -S coordination is supported by Gaussian calculations that indicate a high negative potential over the sulfur atom of the chelators, because the sulfur atom with a negative potential easily binds to  $Cu^{2+}$  (Fig. 2d). Obviously, the chelator occupancy of the SOD1 active site can block the long-range access of  $O_2^{\cdot-}$  to the  $Cu^{2+}$  ion.

In order to prove the coordination of the chelators to the  $Cu^{2+}$  ion in SOD1, we examined the quenching of **LD100** fluorescence *via* titration of the chelator with either  $Cu^{2+}$  or SOD1. Although the fluorescence of **LD100** at 536 nm is progressively quenched with increasing concentrations of the quenchers, the fluorescence is much less quenched by SOD1 than by  $Cu^{2+}$  at the concentrations tested (Fig. 2e). Moreover, a new fluorescent peak appears in the range of 425–475 nm with increasing







**Fig. 2** Characterizations of SOD1 inhibition. (a) Inhibition of the activity of 1  $\mu\text{M}$  SOD1 by 5  $\mu\text{M}$  of chelator, ATSM or DDC in the pH 7.4 buffer containing 1% DMSO. The SOD1 was incubated with the chelators for 60 min at 37  $^{\circ}\text{C}$  prior to measurements.  $n \geq 3$ ,  $*P < 0.05$ , and  $**P < 0.01$ , relative to the control. (b) Visualization of 50  $\mu\text{M}$  LD94 (up) and LD100 (down) taken up by HeLa cells, using confocal microscopy. Incubation occurred for 2 h prior to imaging. Two-photon excitation wavelength: 710 nm. (c) Inhibition of intracellular SOD1 activity. Left, dependences of the intracellular SOD1 inhibition on the concentration of LD29, 34, 94 or 100, right, dependences of the intracellular SOD1 inhibition on the incubation period at 5  $\mu\text{M}$  of LD100.  $n \geq 3$ ,  $*P < 0.05$ , and  $**P < 0.01$ , relative to the control. The control was pH 7.4 buffer containing 1% DMSO; (d) molecular docking simulation on the interactions between a SOD1 molecule and LD100 (up), and DFT calculations of electrostatic potential surfaces for LD94 and 100 (down) (the electron density isosurface is 0.0004 electrons per  $\text{au}^3$ ). (e) Quenching of 50  $\mu\text{M}$  LD100 fluorescence ( $\lambda_{\text{ex}} = 355 \text{ nm}$ ) upon increased addition of 0–50  $\mu\text{M}$   $\text{Cu}^{2+}$  (left) or 0–100  $\mu\text{M}$  SOD1 (right) in pH 7.4 buffer containing 1% DMSO. Inset: Stern–Volmer plots for the quenching of LD100 fluorescence by  $\text{Cu}^{2+}$  or SOD1, where  $F_0$  and  $F$  respectively represent the fluorescence intensity of LD100 (at 536 nm) in the absence and in the presence of  $\text{Cu}^{2+}$  or SOD1. (f) Fluorescence anisotropy of LD100 (50 mM) titrated with SOD1 (0–150  $\mu\text{M}$ ) in pH 7.4 buffer containing 1% DMSO at 37  $^{\circ}\text{C}$ .  $r$  is the fluorescence anisotropy of the LD100–SOD1 system, ( $\lambda_{\text{ex}} = 355 \text{ nm}$ , and slit = 5 nm). (g) Western blotting of the SOD1 protein level and RT-PCR assays of the SOD1 mRNA level. The cells were treated for 24 h with 0.1–50  $\mu\text{M}$  LD18, LD34, LD94 or LD100.

concentrations of the quenchers (Fig. 2e). Because the formation of LD100– $\text{Cu}^{2+}$  complexes can lead to the quenching of the LD100 fluorescence and appearance of this new emission, the fluorescence quenching and the new emission caused by SOD1 can be ascribed to the coordination of LD100 to  $\text{Cu}^{2+}$  in SOD1. On the other hand, the localization into the hydrophobic site of a protein can significantly intensify the fluorescence of

a fluorescent molecule. Thus, the reduced fluorescence quenching of LD100 localized into the active site within the SOD1 molecule is a consequence of the competition between the copper coordination-mediated quenching and the hydrophobic localization-mediated intensification of fluorescence, as indicated by the distinct Volmer–Stern fluorescence quenching plots (the insets in Fig. 2e).




In order to further confirm the binding of the chelators into the interior of SOD1, the affinity of **LD100** for the SOD1 protein was determined using fluorescence anisotropy. The results indicated that the complexes formed with **LD100** have a large stability constant of  $K = 1.91 \times 10^7 \text{ M}^{-1}$  (Fig. 2f, and ESI Fig. 6†), *i.e.*, the affinity of **LD100** for SOD1 reaches 52 nM, which could be ascribed to both the coordination of the **LD100** sulfur atom to the active site  $\text{Cu}^{2+}$  ion and to the H-bonds between **LD100** and the SOD1 residues.

The significant reduction in the intracellular SOD1 activity might also be ascribed to both downregulated expression and upregulated degradation of the SOD1 proteins caused by the exposure to the chelators. To rule out these two possibilities, the levels of both intracellular SOD1 proteins and SOD1 mRNAs were determined, respectively, using western blotting and real-time PCR (RT-PCR). On the one hand, the western blotting results show that the intracellular SOD1 protein level is not altered with the concentrations of the chelators following incubation with the chelators (1–50  $\mu\text{M}$ ) for 24 h (Fig. 2g), indicating that the exposure to increased concentrations of the chelators does not lead to upregulated degradation of the SOD1 proteins. On the other hand, the RT-PCR data shows that the SOD1 mRNA level remains unchanged within the cells exposed to increasing concentrations of the chelators (Fig. 2g, ESI Fig. 7†), revealing that the exposure to increased concentrations of the chelators does not alter the expression of the SOD1 gene. Thus, these results prove that treatment with the chelators does not alter the level of intracellular SOD1, and the dramatic reduction in the intracellular SOD1 activity is caused by the chelator localization into the active site of SOD1.

### Effect of the chelators on the activity of other copper enzymes and proteins

The multiple results described above proved that the chelators are strong copper-coordinating inhibitors of intracellular SOD1 activity. However, the specificity of the SOD1 inhibition remains to be explored. To illustrate the specificity of the intracellular SOD1 inhibition, first, the activity of a typical cuproenzyme CcO within the cells treated with increased concentrations of the chelators was determined with a Human CcO Elisa kit.

The cells were lysed following treatment for 24 h with 50  $\mu\text{M}$  **LD34**, **94** or **100**. The data indicated that the CcO activity in these lysates is almost identical to that in the control (Fig. 3a, ESI Fig. 8†). However, as a comparison, the treatment with 50  $\mu\text{M}$  TM leads to the CcO activity in these lysates being reduced to half of that of the control under the conditions tested, which is well consistent with the previously reported result.<sup>51</sup> Moreover, the exposure to 50  $\mu\text{M}$   $\text{NaN}_3$  (a nonspecifically effective inhibitor of SOD1) results in the complete inactivation of CcO in these lysates (Fig. 3a). This result revealed that the intracellular CcO activity is not attenuated by the treatment with the copper-coordinating inhibitors of SOD1, but is in part or completely inactivated by the nonspecific inhibitors of SOD1. To provide additional evidence for this observation, the CcO activity in the lysates of untreated cells were assayed using a Human CcO Elisa kit following incubation for 30 min



**Fig. 3** Tests of inhibition towards other copper enzymes and proteins. (a) CcO activity was measured using UV-vis absorption spectroscopy in HeLa cells treated for 24 h with 50  $\mu\text{M}$  SOD1 inhibitors.  $n \geq 3$ , and  $**P < 0.01$ , relative to the control. (b) CcO activity in the lysates of the untreated HeLa cells following incubation for 30 min with 50  $\mu\text{M}$  SOD1 inhibitors assayed using a Human CcO Elisa kit.  $n \geq 3$ , and  $**P < 0.01$ , relative to the control. (c) Quenching of 50  $\mu\text{M}$  **LD100** fluorescence ( $\lambda_{\text{ex}} = 355 \text{ nm}$ ) upon addition of 0–150  $\mu\text{M}$  Atox1 in pH 7.4 Tris–HCl containing 1% DMSO; inset, Stern–Volmer plots for the quenching of **LD100** fluorescence by Atox1, where  $F_0$  and  $F$  respectively represent the fluorescence intensity of **LD100** (at 536 nm) in the absence and in the presence of Atox1. (d) Activity of tyrosinase isolated from potato in the presence of 50  $\mu\text{M}$  SOD1 inhibitors following incubation with the chelators for 15 min at 30  $^{\circ}\text{C}$ .

with 50  $\mu\text{M}$  of the SOD1 inhibitors. The data demonstrated that the CcO activity is also not modified with increased addition of the chelators, while TM or  $\text{NaN}_3$  leads to partial or complete inactivation of CcO (Fig. 3b), which is well consistent with the results obtained with the lysates from the treated cells. Because CcO localizes at one terminal of intracellular copper trafficking (ESI Fig. 9†),<sup>57</sup> these results allow us to hypothesize that the copper-coordinating inhibitors of SOD1 do not impair either the intracellular CcO activity or the activities of copper trafficking proteins.

In order to prove the above-mentioned hypothesis, the effect of **LD100** on the copper trafficking activity of Atox1, a typical copper chaperone (ESI Fig. 9†), was examined *via* the fluorescence quenching of **LD100** titrated with Atox1. The data showed




that the fluorescence intensity of **LD100** at 536 nm is almost not reduced, and a new emission peak is not found between 425 and 475 nm with increasing concentrations of Atox1 (Fig. 3c). Obviously, this result was different from that of the treatment of **LD100** with SOD1 (Fig. 2e) and indicated that **LD100** cannot chelate the copper ion in Atox1, revealing that the functions of the intracellular copper trafficking proteins are not modified by SOD1 inhibition.

The observations that the activity of CcO is not altered by the chelators, and that the chelators could not bind to Atox1 suggested no access of the chelators to the copper ions in CcO and Atox1, otherwise the copper ions would be removed or chelated from these two proteins, because their copper affinity is much weaker than that of SOD1.<sup>57</sup> To obtain data to support this suggestion, molecular docking simulations were performed, as in the case of SOD1. The result showed that there is not any access of the copper-coordinating inhibitors of SOD1 to the copper sites in these two protein molecules. Thus, the SOD1 inhibitors cannot inactivate these two copper proteins because they neither remove copper nor coordinate to copper in the proteins.

In addition, we observed the effect of the copper-coordinating inhibitors of SOD1 on the activity of tyrosinase from potato. Tyrosinase, which catalyzes the reaction of L-tyrosine with water, is a dicopper-containing multisubunit enzyme whose structures are conserved across all species. The data showed that the incubation for 0–20 min with 50  $\mu\text{M}$  **LD94** or **100** leads to only a <10% reduction in the activity relative to the control, whereas 50  $\mu\text{M}$  TM results in complete inactivation of the enzyme under the conditions tested (Fig. 3d), indicating that the copper-coordinating inhibitors **LD94** and **100** almost do not at all inactivate tyrosinase, as supported by the molecular docking results (ESI Fig. 10†). Taken together with the observations performed with both CcO and Atox1, the copper-chelating agents not only do not inhibit both CcO and tyrosinase, but also do not impair the functions of the trafficking proteins that transfer copper to these two kinds of enzymes for their maturation, *i.e.*, the activity of the intracellular SOD1 can specifically be inhibited by the chelators.

### Changes of intracellular basal ROS levels

SOD1 catalyzes the dismutation of  $\text{O}_2^{\cdot-}$  into  $\text{H}_2\text{O}_2$  and  $\text{O}_2$ . Thus, one of the consequences of the specific SOD1 inhibition should be that the intracellular  $\text{O}_2^{\cdot-}$  level is elevated and the  $\text{H}_2\text{O}_2$  level is decreased. To prove this expectation, the intracellular  $\text{O}_2^{\cdot-}$  and  $\text{H}_2\text{O}_2$  levels were evaluated, respectively, with the  $\text{O}_2^{\cdot-}$ - and  $\text{H}_2\text{O}_2$ -sensitive fluorescence dyes dihydroethidium (DHE) and dichlorofluorescein ( $\text{H}_2\text{DCFDA}$ ). The intracellular fluorescence intensity of these dyes was measured using flow cytometry. The fluorescence data shows that (1) treatment for 24 h with the different 5  $\mu\text{M}$  inhibitors results in significantly elevated  $\text{O}_2^{\cdot-}$  and decreased  $\text{H}_2\text{O}_2$  levels within the cells (Fig. 4a), (2) the  $\text{O}_2^{\cdot-}$  level is increased and the  $\text{H}_2\text{O}_2$  level is decreased with increasing concentrations of the inhibitors (Fig. 4b), and (3) treatment with 1  $\mu\text{M}$  **LD94**, and **100** leads the  $\text{O}_2^{\cdot-}$  and  $\text{H}_2\text{O}_2$  levels to be elevated to 150–160% of and reduced to 60–70% of



**Fig. 4** Effects of the SOD1 inhibition on intracellular ROS levels and pERK1/2. (a) The DHE or DCFDA fluorescence intensity in the cells treated for 24 h with the SOD1 inhibitors of 5  $\mu\text{M}$ . The DHE and DCFDA fluorescence intensity is positively correlated, respectively, with  $\text{O}_2^{\cdot-}$  and  $\text{H}_2\text{O}_2$  levels.  $n \geq 3$ ,  $*P < 0.05$ , and  $**P < 0.01$ , relative to the control. (b) The dependences of the DHE and DCFDA fluorescence intensity in the treated cells for 24 h on the concentrations of **LD34**, **94** and **100**.  $n \geq 3$ ,  $*P < 0.05$ , and  $**P < 0.01$ , relative to the control. (c) The phosphorylation level of ERK1/2 in the treated HeLa cells is changed with types and concentrations of the SOD1 inhibitors. Quantification of the western bands was performed using the Image G software.

the control, respectively. These results indicate that both the increase of  $\text{O}_2^{\cdot-}$  and the decrease of  $\text{H}_2\text{O}_2$  levels within the treated cells can be not only correlated with types of SOD1 inhibitors, but also depend on their concentrations, as observed for the intracellular SOD1 inactivation (Fig. 2c). Moreover, the reduction in the  $\text{H}_2\text{O}_2$  level (**LD100** > **94** > **34** > **27** ~ **61** > **29** > **25** ~ **72** > **18**) is well consistent with the  $\text{IC}_{50}$  values of the intracellular SOD1 inhibition (Fig. 2c). Therefore, the intracellular basal levels of  $\text{O}_2^{\cdot-}$  and  $\text{H}_2\text{O}_2$  can reasonably be regulated with the small molecules without the stimulation of either exogenous  $\text{H}_2\text{O}_2$  or growth factors.

### Regulation of intracellular ERK signaling

$\text{H}_2\text{O}_2$  inactivates the protein tyrosine phosphatases *via* oxidizing the –SH groups in their active site cysteine residues, thereby regulating ERK signaling pathways.<sup>1–4</sup> Doñate *et al.*





reported that the decreased intracellular  $\text{H}_2\text{O}_2$  levels induced by ATN-224 inhibition of SOD1 can cause the downregulation of ERK phosphorylation in EGF-stimulated cells.<sup>30</sup> Thus, we selected the ERK pathway to explore the potential of our inhibitors in ROS signaling research. At which level the alteration of intracellular ROS could affect the ROS signaling pathway is an important issue in ROS signaling research.

The phosphorylation of ERK1/2 (pERK1/2) was examined following the treatment for 24 h of HeLa cells with five chelators at different concentrations. As shown in Fig. 4, a slight reduction of ERK1/2 phosphorylation (about 10%) was observed in 0.1  $\mu\text{M}$  LD34- or LD100-treated HeLa cells which also exhibit about a 15% reduction in  $\text{H}_2\text{O}_2$  level relative to the untreated cells, whereas the levels of ERK1/2 proteins in the treated cells does not change with types and concentrations of the inhibitors. Moreover, the reduction in pERK1/2 (about 75% at 50  $\mu\text{M}$  LD100) is enhanced with increasing concentrations of the chelators (Fig. 4c), as the intracellular  $\text{H}_2\text{O}_2$  level is further decreased (about 45%, Fig. 4b). It is notable that the alteration of pERK in cells before and after the treatment with the inhibitors is so significant that no EGF stimulation is required to augment the differentiation. These results revealed that the specific inhibitors of SOD1 might provide a powerful tool for controlling intracellular ROS levels in the regulation and research of ROS signaling.

### Promotion of cancer cell apoptosis

The effect of the copper-coordinating inhibition of SOD1 on cancer cell growth was observed *via* flow cytometry, because SOD1 has been established as one of the anti-cancer targets. The data showed that the normal cells COS-7 only display a slight elevation in apoptosis following exposure to 10 or 50  $\mu\text{M}$  LD100 for 24 h (Fig. 5a), while the apoptosis of the cancer cells (HeLa) treated with 0–50  $\mu\text{M}$  LD100 for 24 h is significantly increased from 5.85% to 13.54% (Fig. 5b). In addition, the treatment with 50  $\mu\text{M}$  LD94 under the same conditions leads only to a slight increase in the apoptosis of HeLa cells (Fig. 5c). These results indicated that the apoptosis depends not only on the types and concentrations of the chelators, but also likely on the types of cells tested. The cancer cell lines may display more noticeable apoptosis than normal cell lines following treatment with LD100. The promotion of cancer cell apoptosis might be due to the alterations of the basal levels of intracellular ROS *via* the SOD1 inhibition (Fig. 4a and b). The reduced  $\text{H}_2\text{O}_2$  level may lead to programmed cell death through inhibiting the ERK1/2 signaling pathways, and the increased  $\text{O}_2^{\cdot-}$  level may also promote apoptosis probably because of the formation of peroxynitrite *via* the reaction of  $\text{O}_2^{\cdot-}$  with NO.<sup>51</sup>

The chelators designed in this study exhibit high selectivity for  $\text{Cu}^{2+}$  over the other divalent metal ions tested, and form  $\text{Cu}^{2+}$  complexes whose stability constants are much higher than the copper affinity of the proteins including SOD1, CcO and Atox1. The tests in both solutions and cells indicated that the chelators inactivate SOD1 *via* coordinating to the  $\text{Cu}^{2+}$  ion in the SOD1 active site, blocking the redox cyclic reaction between the  $\text{Cu}^{2+}$  ion and the substrate  $\text{O}_2^{\cdot-}$ , and disrupting the noncovalent




Fig. 5 Effects of SOD1 inhibition on cell apoptosis. (a) COS-7 cells, and 50  $\mu\text{M}$  LD100. (b) HeLa cells, and 10–50  $\mu\text{M}$  LD100. (c) HeLa cells, and 50  $\mu\text{M}$  LD94. Q1–4, cell debris, cells in the end stage of apoptosis, surviving cells, and apoptotic cells, respectively. Apoptotic cells were identified *via* dual-staining with recombinant FITC-conjugated Annexin V-PI.

interactions between the  $\text{Cu}^{2+}$ -bound  $\text{O}_2^{\cdot-}$  and the residue Arg141 in SOD1. However, the copper-coordinating inhibition of SOD1 not only does not inactivate both CcO and tyrosinase, but also does not impact on their copper trafficking protein Atox1. The reduced ERK1/2 phosphorylation in the cells treated with the chelators is a consequence of the reduced  $\text{H}_2\text{O}_2$  level.





Moreover, the inactivation of SOD1 results in inhibitor concentration-dependent elevation and reduction, respectively, of the intracellular  $O_2^{\bullet-}$  and  $H_2O_2$  levels which promotes cancer cell apoptosis.

The functional groups that play a key role in the SOD1 inhibition can be identified based on both the stability constants of the copper complexes and the  $IC_{50}$  data of the SOD1 inhibition (Table 1). First, the group  $-C=S$  in the chelators is essential for tight chelation to copper, because the copper complexes formed *via* the coordination of the chelator  $-C=S$  group have stability constants of at least two orders of magnitude more than those *via*  $-C=O$  (LD27). The localization of the chelators in the SOD1 active site leads  $-C=S$  to coordinate to the SOD1  $Cu^{2+}$  ion, as indicated by both molecular docking simulations (Fig. 2d) and fluorescent titrations of the chromone-containing chelators with SOD1 (Fig. 2e). The coordination of  $-C=S$  in the chelators makes the  $Cu^{2+}$  ion in SOD1 become redox-inert, although the coordination of this group to  $Cu^{2+}$  in SOD1 ( $Cu^{2+}$ -S distances = 3.46–4.27 Å, Fig. 1c and 2d) may be weaker than that in copper complexes ( $Cu^{2+}$ -S bonds = 2.253–2.278 Å) because of the steric restriction from the SOD1 protein structure. Then, the introduction of the H-bonding acceptor (chromone in LD93, 94, and 100) and donor (phenolic hydroxyl in LD29, 34, 74, 94, and 100) into the chelators can significantly decrease the  $IC_{50}$  values of their SOD1 inhibition because the formation of H-bonds between these groups and the SOD1 residues (indicated in Fig. 1c and 2d) can disrupt the noncovalent interactions including the H-bond between the  $Cu^{2+}$ -bound  $O_2^{\bullet-}$  and the SOD1 residue Arg141 (Fig. 1a). Unexpectedly, the chromone facilitates not only monitoring cell uptake of the chelators through visualization, but also enhancing the SOD1 inhibition *via* the occupancy of the substrate channel in SOD1. In addition, the chlorine modification of the phenol results in the increased uptake of cells and decreased  $IC_{50}$  values of SOD1 inhibition, since this modification can intensify the H-bonding interaction of the phenolic hydroxyl with the amide group between Pro60 and His61 in SOD1.

The above-mentioned interactions between a SOD1 molecule and each of the chelators could underlie the specific copper-coordinating inhibition of intracellular SOD1 activity. This specific SOD1 inhibition is supported by multiple observations. First, the activity of the copper enzymes CcO and tyrosinase is completely not attenuated by the chelators (Fig. 3), indicating that the chelators also do not impair the functions of the copper trafficking proteins, as indicated by the test with Atox1 (Fig. 3). Then, the intracellular SOD1 activity is continuously decreased with increasing concentrations of the chelators (Fig. 2c). Moreover, the intracellular  $O_2^{\bullet-}$  level rises and  $H_2O_2$  level falls also in a chelator concentration-dependent manner (Fig. 4b). However, a possibility that cannot be ruled out is that the chelators may remove or chelate copper from the copper chaperone for SOD1 (CCS) or target the CCS-SOD1 interaction interface, as revealed currently with a small molecule.<sup>60</sup> Obviously, the disruption of the copper trafficking function of CCS can also reduce maturation of the nascent SOD1 protein. This copper-coordinating or CCS-SOD1 interface-targeting

inhibition of CCS is actually also able to specifically attenuate the activity of the intracellular total SOD1. Consequently, the chelators are a specific inhibitor of intracellular SOD1 activity.

Many studies directly expose cells to  $H_2O_2$  at concentrations much higher than the intracellular basal level of  $H_2O_2$ , or stimulate cells to produce high levels of  $H_2O_2$  with growth factors or cytokines to explore or to regulate ROS signaling pathways.<sup>13–27</sup> Our results reveal that the specific copper-coordinating inhibition of SOD1 activity can significantly decrease the intracellular basal level of  $H_2O_2$ . The chelator concentration-dependent decrease in the  $H_2O_2$  level is parallel to the chelator concentration-dependent reduction in pERK1/2 and the dependent elevation in the apoptosis of HeLa cells (Fig. 4 and 5), *i.e.*, the specific and efficient inhibition of intracellular SOD1 activity can regulate the  $H_2O_2$  signaling pathways including ERK1/2 *via* directly decreasing the intracellular basal  $H_2O_2$  levels, rather than *via* dramatically increasing intracellular  $H_2O_2$  levels by the stimulations of added  $H_2O_2$  or growth factors. Therefore, the small molecules designed here can significantly regulate both ROS ERK signaling and apoptosis of cancer cells under conditions where no amplification of ROS signaling is required.

## Conclusions

A kind of specific and efficient copper-coordinating inhibitor of intracellular SOD1 activity was designed based on the structure and catalytic redox cycle of the active site in SOD1. The coordination of the copper in SOD1 to the inhibitors leads to the disruption of the  $Cu^{2+}/Cu^+$  catalytic cycle essential for  $O_2^{\bullet-}$  dismutation. The copper-coordinating and H-bonding groups in the inhibitors play key roles in the specific inactivation of SOD1. The specific SOD1 inhibition directly changes intracellular basal levels of  $H_2O_2$  without external stimulations of either  $H_2O_2$  or growth factors, which enables us to conveniently monitor and regulate both ROS signaling and cancer cell apoptosis. Thus, the copper-coordinating agents might become a powerful tool in further understanding and regulation of ROS signaling, oxidative stress, and redox-involved apoptosis and pathology.

## Materials and methods

### General methods

All reagents were purchased from commercial sources (*e.g.*, Sigma) and directly used unless stated otherwise. Solvents were purified *via* the most used methods. All of the solutions and buffers were prepared using deionized water that was passed through a Millipore-Q ultrapurification system. Elementary analysis was carried out on a Vario EL III elementary analysis instrument. UV-Vis spectra were recorded on an Analytik Jena Specord 210 spectrophotometer (Analytik Jena AG).  $^1H$  and  $^{13}C$  NMR spectra were measured on a Varian Mercury 400 spectrometer. The MS data was obtained using a Quattro II ESI mass spectrometer (Waters, USA).



### Assays of SOD1 activity

SOD1 activity was determined by measuring the inhibition of the reduction of the water-soluble tetrazolium salt, WST-1 (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-phenyl)-2H-tetrazolium, monosodium salt), which produced a water-soluble formazan dye upon reduction with  $O_2^{\bullet -}$ . The determinations were performed with a HT Superoxide Dismutase Assay Kit (Trevigen) that is specific to SOD1. The concentration of proteins was determined using a Biorad DC protein assay kit. Bovine SOD1 (Sigma), which has been proved to be equivalent to human SOD1,<sup>60</sup> was used to generate a standard curve. The results represent the mean  $\pm$  SD of at least three parallel experiments in which each condition was assayed in duplicate.

### Assays of CcO activity

The CcO activity in Hela cells was measured using the UV-vis spectrophotometer<sup>61</sup> and cytochrome c oxidase assay kit<sup>62</sup> (Human CcO Elisa kit, Sigma). Using different testing methods because of the sensitivity for the substrate, CcO activity was measured using UV-vis absorption spectra in the cells with inhibitors. The cells were lysed following incubation for 24 h with 50  $\mu$ M LD34, LD94, LD100, TM or  $NaN_3$ . Ferrocycytochrome c (reduced cytochrome c with dithiothreitol) was then added to the sample, and the CcO activity was determined by measuring the change of UV absorption at 550 nm. The difference in extinction coefficients between reduced and oxidized cytochrome c is 21.84 at 550 nm.<sup>61</sup> The CcO activity in the lysates of untreated cells was assayed following incubation for 30 min with 50  $\mu$ M of the SOD1 inhibitors by using the Human CcO Elisa. One unit of CcO activity was defined as the oxidation of 1.0  $\mu$ M of ferrocycytochrome c per min at pH 7.4 at 25 °C. The results represent the mean  $\pm$  SD of at least three experiments in which each condition was assayed in duplicate, the control was a blank containing 1% DMSO.

### Assays of tyrosinase activity

The tyrosinase enzyme was isolated from potato and purified by using the method described by the literature.<sup>63</sup> Tyrosinase activity was determined through measuring the oxidation of 3,4-dihydroxyphenylalanine (L-DOPA, Sigma), which was constructed by Pomerantz *et al.*:<sup>64</sup> 50  $\mu$ L of enzyme extract was added to 450  $\mu$ L of 0.05 M phosphate buffer (pH 6.8) containing 50  $\mu$ M chelators, and the mixture was preincubated at 30 °C for 10 min, 500  $\mu$ L of 5 mM L-DOPA solution was then added, and the increase in absorption at 475 nm ( $\epsilon = 3600 \text{ M cm}^{-1}$ ) due to the formation of DOPA chrome was monitored as a function of time. The initial rate could be used to estimate the tyrosinase activity and the control was a blank containing 1% DMSO.

### Fluorescence quenching assays

Fluorescence spectra were acquired on a Cary Eclipse fluorescence spectrophotometer (Varian, USA). Quenching of 50  $\mu$ M LD100 fluorescence ( $\lambda_{\text{ex}} = 355 \text{ nm}$ ) was measured upon addition of 0–50  $\mu$ M  $Cu^{2+}$ , 0–100  $\mu$ M SOD1 or 0–150  $\mu$ M Atox1 for 15–30 min in 20 mM Tris-HCl (pH 7.4) containing 1% DMSO. All

measurements were conducted at 37.0 °C, the fluorescence emission spectra were integrated from 400 to 700 nm.

### Fluorescence anisotropy

Fluorescence anisotropy was performed with a Cary Eclipse fluorescence spectrophotometer (with polarizer device, Varian, USA), anisotropy data were obtained using an excitation wavelength of 355 nm, and the fluorescence emission was monitored from 532 to 542 nm. The final values were from an average of three scans. Anisotropy values were averaged over the emission range. The *G*-factor was measured to be 1.73 on average before each experiment.<sup>65</sup> All of the samples were in a 20 mM Tris-HCl buffer (pH 7.4). Samples were stirred continuously in a 10 mm Spectrosil quartz cuvette. All measurements were done at 37 °C, which was maintained with a circulating bath. The analysis of binding parameters using fluorescence anisotropy and formula derivation can be found in ESI.†

### Western blotting of SOD1 and protein phosphorylation

HeLa cells were washed with cold PBS and lysed (175 mM NaCl, 25 mM HEPES, pH 7.4, 10% glycerol, 5 mM EDTA, 1% Triton X, 50 mM sodium fluoride, and 5 mM sodium orthovanadate). The cells lysates were then scraped using a plastic cell lifter, transferred to labeled microfuge tubes and spun at 12 000 rpm at 4 °C for 10 min. The supernatant was then transferred to a fresh tube and the total proteins were estimated *via* Bradford assay (BCA Assay, Pierce Biotechnology Inc). The cell lysates prepared above were mixed with electrophoresis SDS sample buffer (Novex) and separated on 10% Novex SDS-PAGE Tris-glycine gels. The proteins were transferred to PVDF membranes and blocked with BSA solution in TBST before immunoblotting for total or phospho-specific proteins. For the detection of signal transduction molecules, membranes were probed with polyclonal antisera against SOD1, ERK1/2 or phospho-ERK1/2 at 1:1000. The secondary antiserum was goat anti-rabbit-HRP at 1:2000. Blots were developed using a DAB chromogenic reagent kit and imaged on a GeneGenome Chemiluminescence Imager (Syngene, Cambridge). The expression of  $\beta$ -actin was used as a protein loading control when necessary.

### RT-PCR

After HeLa cells reached 80% confluence in 96-well plates, the FBS-containing medium was replaced with a FBS-free medium, and incubated for 24 h. Then, chelators (0.1, 1, 10, and 20  $\mu$ M) were added into the wells (6 parallel wells tested), and further incubated for 24 h at 37 °C. The total RNA was purified from the incubated Hela cells using the High Pure RNA Isolation Kit (Roche). Real-time PCR was performed utilizing the Fast Start Essential DNA Green Master (Roche) with 5  $\mu$ L of cDNA, and 0.2  $\mu$ M primers in a total volume of 20  $\mu$ L in a LightCycler 96 Instrument (Roche). Purified RNA (1  $\mu$ g) was reverse transcribed into cDNA by the transcriptor first strand cDNA synthesis Kit (Roche) in a total volume of 20  $\mu$ L. The amplification was monitored *via* SYBR Green fluorescence. Correct amplification was monitored *via* post-run melt curve analysis. A 3-step cycling protocol (95 °C, 10 s; 59 °C, 10 s; and 72 °C, 10 s) was used. The



annealing temperature could surpass 90% amplification efficiency, and correct amplification was monitored using post-run melt curve analysis. The level of expression of each of the transporters was normalized to that of  $\beta$ -actin assessed by the same assay. The primers for SOD1 were 5'-AAGGCCGTGTGCGTGCTGAA-3' and 5'-GGCCCACCGTGTTTCTGGA-3'. The results represent the mean  $\pm$  SD of at least five experiments in which each condition was assayed in duplicate.

### Measurements of intracellular ROS levels

Hela cells were incubated with 0.1, 0.5, 1, or 2  $\mu$ M LD100 for 24 h, and then, trypsinized, washed with PBS, counted, and resuspended in PBS. For superoxide measurements, dihydroethidium (DHE) (Sigma) was added to the cells at 5  $\mu$ M for 20 min. For H<sub>2</sub>O<sub>2</sub> measurements, dichloro-dihydro-fluorescein diacetate (DCFH-DA) (Sigma) at 5  $\mu$ M was added to the cells for 20 min. After incubation with the respective dyes, the cells were extensively washed and analyzed using CytoFLEX (Beckman Coulter, Inc. USA). The initial data can be found in ESI.†

### Apoptosis assays

Hela and COS-7 cells were incubated with 10, 25, 50, or 75  $\mu$ M LD100 for 24 h, then washed with PBS, and centrifuged at 1000 *g* for 5 min, resuspended in ice-cold 70% ethanol/PBS, centrifuged at 800 *g* for another 6 min, and resuspended in PBS. These cells were then incubated with propidium iodide (PI) and fluorescein isothiocyanate (FITC)-labeled annexin V for 30 min at 37 °C. Excess PI and annexin V were then washed off; the cells were fixed, and the stained cells were analyzed *via* flow cytometry using CytoFLEX (Beckman Coulter, Inc. USA) equipped with a 488 nm argon laser light source, a 525 nm bandpass filter for FITC fluorescence, and a 615 nm bandpass filter for PI fluorescence using CellQuest software.

## Conflict of interest

The authors declare no competing financial interest.

## Acknowledgements

This study is supported by NSFC (No. 21271079, 21001047, and 21072074), by Natural Science Foundation of Hubei Province of China (No. 2015CFB305) and by self-determined research funds of CCNU from the colleges' basic research and operation of MOE (No. CCNU14A05004, CCNU14KFY003, and CCNU15A05016). We thank Prof. Yangzhong, Liu at USTC for providing AToX1.

## References

- 1 B. D'Autreaux and M. B. Toledano, *Nat. Rev. Mol. Cell Biol.*, 2007, **8**, 813–824.
- 2 E. A. Veal, A. M. Day and B. A. Morgan, *Mol. Cell*, 2007, **26**, 1–14.
- 3 B. C. Dickinson and C. J. Chang, *Nat. Chem. Biol.*, 2011, **7**, 504–511.
- 4 A. Bindoli and M. P. Rigobello, *Antioxid. Redox Signaling*, 2013, **18**, 1557–1593.
- 5 D. Trachootham, W. Lu, M. A. Ogasawara, R. D. Nilsa and P. Huang, *Antioxid. Redox Signaling*, 2008, **10**, 1343–1374.
- 6 K. M. Holmstrom and T. Finkel, *Nat. Rev. Mol. Cell Biol.*, 2014, **15**, 411–421.
- 7 T. W. Miller, J. S. Isenberg and D. D. Roberts, *Chem. Rev.*, 2009, **109**, 3099–3124.
- 8 S. S. Sabharwal and P. T. Schumacker, *Nat. Rev. Cancer*, 2014, **14**, 709–721.
- 9 S. C. Gupta, H. David, P. Sridevi, P. Byoungduck, K. Wonil and B. B. Aggarwal, *Antioxid. Redox Signaling*, 2012, **16**, 1295–1322.
- 10 C. K. Glass, K. Saijo, B. Winner, M. C. Marchetto and F. H. Gage, *Cell*, 2010, **140**, 918–934.
- 11 M. Noble, M. Mayer-Pröschel, Z. Li, T. Dong, W. Cui, C. Pröschel and C. Folts, *Free Radical Biol. Med.*, 2015, **79**, 300–323.
- 12 C. R. Reczek and N. S. Chandel, *Curr. Opin. Cell Biol.*, 2015, **33**, 8–13.
- 13 Z. A. Wood, L. B. Poole and P. A. Karplus, *Science*, 2003, **300**, 650–653.
- 14 H. A. Woo, H. Z. Chae, S. C. Hwang, K. S. Yang, S. W. Kang, K. Kim and S. G. Rhee, *Science*, 2003, **300**, 653–656.
- 15 N. R. Leslie, D. Bennett, Y. E. Lindsay, H. Stewart, A. Gray and C. P. Downes, *EMBO J.*, 2003, **22**, 5501–5510.
- 16 E. A. Veal, V. J. Findlay, A. M. Day, S. M. Bozonet, J. M. Evans, J. Quinn and B. A. Morgan, *Mol. Cell*, 2004, **15**, 129–139.
- 17 H. Kamata, S. I. Honda, S. Maeda, L. Chang, H. Hirata and M. Karin, *Cell*, 2005, **120**, 649–661.
- 18 K. Chen, M. T. Kirber, H. Xiao, Y. Yang and J. F. Keaney, *J. Cell Biol.*, 2008, **181**, 1129–1139.
- 19 J. Cao, J. Schulte, A. Knight, N. R. Leslie, A. Zagozdzon, R. Bronson and C. A. Neumann, *EMBO J.*, 2009, **28**, 1505–1517.
- 20 H. A. Woo, S. H. Yim, D. H. Shin, D. Kang, D. Y. Yu and S. G. Rhee, *Cell*, 2010, **140**, 517–528.
- 21 D. Anastasiou, G. Poulgiannis, J. M. Asara, M. B. Boxer, J. K. Jiang, M. Shen and C. J. Thomas, *Science*, 2011, **334**, 1278–1283.
- 22 B. C. Dickinson, J. Peltier, D. Stone, D. V. Schaffer and C. J. Chang, *Nat. Chem. Biol.*, 2011, **7**, 106–112.
- 23 T. J. Cohen, A. W. Hwang, T. Unger, J. Q. Trojanowski and V. M. Lee, *EMBO J.*, 2012, **31**, 1241–1252.
- 24 M. C. Sobotta, W. Liou, S. Stöcker, D. Talwar, M. Oehler, T. Ruppert and T. P. Dick, *Nat. Chem. Biol.*, 2014, **11**, 64–70.
- 25 J. Kwon, S. R. Lee, K. S. Yang, Y. Ahn, Y. J. Kim, E. R. Stadtman and S. G. Rhee, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 16419–16424.
- 26 G. J. DeYulia, J. M. Carcamo, O. Borquez-Ojeda, C. C. Shelton and D. W. Golde, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 5044–5049.
- 27 R. Wani, J. Qian, L. Yin, E. Bechtold, S. B. King, L. B. Poole and C. M. Furdui, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 10550–10555.
- 28 J. M. McCord and I. Fridovich, *J. Biol. Chem.*, 1969, **244**, 6049–6055.





- 29 Y. Sheng, I. A. Abreu, D. E. Cabelli, M. J. Maroney, A. F. Miller, M. Teixeira and J. S. Valentine, *Chem. Rev.*, 2014, **114**, 3854–3918.
- 30 J. C. Juarez, M. Manuia, M. E. Burnett, O. Betancourt, B. Boivin, D. E. Shaw and F. Doñate, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 7147–7152.
- 31 A. R. Reddi and V. C. Culotta, *Cell*, 2013, **152**, 224–235.
- 32 T. Fukai and M. Ushio-Fukai, *Antioxid. Redox Signaling*, 2011, **15**, 1583–1606.
- 33 V. L. Kinnula and J. D. Crapo, *Free Radical Biol. Med.*, 2004, **36**, 718–744.
- 34 F. D. Oakley, D. Abbott, Q. Li and J. F. Engelhardt, *Antioxid. Redox Signaling*, 2009, **11**, 1313–1333.
- 35 M. J. Hitchler and F. E. Domann, *Antioxid. Redox Signaling*, 2014, **20**, 1590–1598.
- 36 P. Huang, L. Feng, E. A. Oldham, M. J. Keating and W. Plunkett, *Nature*, 2000, **407**, 390–395.
- 37 R. Somwar, H. Erdjument-Bromage, E. Larsson, D. Shum, W. W. Lockwood, G. Yang, C. Sander, O. Ouerfelli, P. J. Tempst, H. Djaballah and H. E. Varmus, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 16375–16380.
- 38 M. Kelner and N. Alexander, *J. Biol. Chem.*, 1986, **261**, 1636–1641.
- 39 J. D. Rothstein, L. A. Bristol, B. Hosler, R. H. Brown and R. W. Kunkel, *Proc. Natl. Acad. Sci. U. S. A.*, 1994, **91**, 4155–4159.
- 40 A. Warshawsky, I. Rogachev, Y. Patil, A. Baszkin, L. Weiner and J. Gressel, *Langmuir*, 2001, **17**, 5621–5635.
- 41 V. Lushchak, H. Semchyshyn, O. Lushchak and S. Mandryk, *Biochem. Biophys. Res. Commun.*, 2005, **338**, 1739–1744.
- 42 A. Dumay, V. Rincheval, P. Trotot, B. Mignotte and J. L. Vayssiere, *Free Radical Biol. Med.*, 2006, **40**, 1377–1390.
- 43 J. C. Juarez, O. Betancourt, S. R. Pirie-Shepherd, X. Guan, M. L. Price, D. E. Shaw and F. Doñate, *Clin. Cancer Res.*, 2006, **12**, 4974–4982.
- 44 F. Donate, J. C. Juarez, M. E. Burnett, M. M. Manuia, X. Guan, D. E. Shaw and A. P. Mazar, *Br. J. Cancer*, 2008, **98**, 776–783.
- 45 L. Mandinov, A. Mandinova, S. Kyurkchiev, D. Kyurkchiev, I. Kehayov, V. Kolev and M. J. Post, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 6700–6705.
- 46 Q. Pan, C. G. Kleer, K. L. van Golen, J. Irani, K. M. Bottema, C. Bias and G. J. Brewer, *Cancer Res.*, 2002, **62**, 4854–4859.
- 47 A. Glassauer, L. A. Sena, L. P. Diebold, A. P. Mazar and N. S. Chandel, *J. Clin. Res. Lett.*, 2014, **124**, 117–128.
- 48 V. E. Lee, J. M. Schulman, E. I. Stiefel and C. C. Lee, *J. Inorg. Biochem.*, 2007, **101**, 1707–1718.
- 49 R. A. Campbell, M. S. Gordon, O. Betancourt, J. Juarez, F. Donate, A. Mazar and J. R. Berenson, *Cancer Res.*, 2006, **66**, 1141.
- 50 S. A. Lowndes, A. Adams, A. Timms, N. Fisher, J. Smythe, S. M. Watt and M. Middleton, *Clin. Cancer Res.*, 2008, **14**, 7526–7534.
- 51 K. Lee, M. M. Briehl, A. P. Mazar, I. Batinic-Haberle, J. S. Reboucas, B. Glinsmann-Gibson and M. E. Tome, *Free Radical Biol. Med.*, 2013, **60**, 157–167.
- 52 M. V. Chidambaram, G. Barnes and E. Frieden, *J. Inorg. Biochem.*, 1984, **22**, 231–239.
- 53 K. D. Bissig, T. C. Voegelín and M. Solioz, *FEBS Lett.*, 2001, **507**, 367–370.
- 54 H. M. Alvarez, Y. Xue, C. D. Robinson, M. A. Canalizo-Hernández, R. G. Marvin, R. A. Kelly and T. V. O'Halloran, *Science*, 2010, **327**, 331–334.
- 55 K. Kawamura, Y. Kuroda, M. Sogo, M. Fujimoto, T. Inui and T. Mitsui, *Biochem. Biophys. Res. Commun.*, 2014, **452**, 181–185.
- 56 P. J. Hart, M. M. Balbirnie, N. L. Ogihara, A. M. Nersissian, M. S. Weiss, J. S. Valentine and D. Eisenberg, *Biochemistry*, 1999, **38**, 2167–2178.
- 57 L. Banci, I. Bertini, S. Ciofi-Baffoni, T. Kozyreva, K. Zovo and P. Palumaa, *Nature*, 2010, **465**, 645–648.
- 58 B. M. Paterson and P. S. Donnelly, *Chem. Soc. Rev.*, 2011, **40**, 3005–3018.
- 59 J. Heinze, *Angew. Chem., Int. Ed.*, 1984, **23**, 831–847.
- 60 J. Wang, C. Luo, C. Shan, Q. You, J. Lu, S. Elf and H. Kang, *Nat. Chem.*, 2015, **7**, 968–979.
- 61 L. Smith and P. W. Camerino, *Biochemistry*, 1963, **2**, 1428–1432.
- 62 S. I. Ogura, K. Maruyama, Y. Hagiya, Y. Sugiyama, K. Tsuchiya, K. Takahashi and T. Tanaka, *BMC Res. Notes*, 2011, **4**, 66–70.
- 63 Y. J. Xuan, Y. Endo and K. Fujimoto, *J. Agric. Food Chem.*, 2002, **50**, 6575–6578.
- 64 S. H. Pomerantz, *J. Biol. Chem.*, 1963, **238**, 2351–2357.
- 65 J. R. Lakowicz, *Principles of Fluorescence Spectroscopy*, Springer Science, New York, 2007, ch. 10.

